New Product Introduction: KANEKA KanCapA 3G Affinity Sorbent

September 10, 2018 KANEKA♦ KanCapA 3G sorbent comprises a recombinant Protein A ligand covalently attached to a rigid cellulose matrix. This ensures stability over a high number of cycles and provides high flow performance at low pressure making the sorbent compatible with the process requirements for large scale mAb manufacture in both batch and continuous processing using... Read more

Increase Efficiency and Accelerate Drug Discovery Research with Olympus NoviSight™ 3D Cell Analysis Software

September 10, 2018 3D imaging technology provides images of the cell cluster down to the nuclei while mitigating drug discovery risks Olympus Corporation today announced the U.S.-only launch of a new 3D cell analysis technology with ability to accurately analyze 3D cell cultures down to the nuclei, improving the reliability and accuracy of the entire... Read more

A new way of FIB-processing

Creating TEM lamellae with the new Ion-sculptor FIB column of ZEISS Crossbeam Knowledge News The ZEISS Crossbeam FIB-SEM combines the powerful imaging and analytical performance of a field emission scanning electron microscope (FE-SEM) column with the superior processing ability of a next-generation focused ion beam (FIB). It therefore enables applications like imaging & analytics, tomography as... Read more

Pushing the Boundaries in Automation – First Glimpse of Next-Generation Solution for Endotoxin Detection at PDA 2018

Walkersville, MD (USA)/Basel (CH), 3 September 2018 – Lonza will reveal its next-generation endotoxin automation solution, PyroTec™ Pro Robotic Solution at the Parenteral Drug Association (PDA) Global Conference on Pharmaceutical Microbiology from 15-16 October, in Bethesda, MD (USA). At Booth #308 Lonza experts will demonstrate how the company’s instruments, reagents and software are integrated into... Read more

Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine

Basel, 30 August 2018 Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis Hemlibra is the first medicine to demonstrate superior efficacy to prior factor VIII prophylaxis based on a statistically significant reduction in... Read more